NEONeoGenomics, Inc.

1. Oct 5, 2026CEO Transition On September 30, 2026, the Board of Directors (the “Board”) of the Company approved the appointment of Warren Stone, the Company’s current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.Earnings release · Form 8-K
2. Aug 11, 2026On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.Director or officer change · Form 8-K
3. Jul 28, 2026NeoGenomics Reports Second Quarter 2026 Results.Earnings release · press release
4. Jul 20, 2026As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse.Regulation FD disclosure · Form 8-K
5. Jun 25, 2026On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.Director or officer change · Form 8-K
6. Jun 22, 2026Indenture and Notes On June 22, 2026, NeoGenomics, Inc. (the “Company”) completed its previously announced offering of $275.0 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2032 (the “Initial Notes”)Material agreement entered · Form 8-K
7. Jun 17, 2026On June 17, 2026, NeoGenomics, Inc. (the “Company”) issued a press release relating to the pricing of its offering of convertible senior notes due 2032 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible Notes …Other event · Form 8-K
8. Jun 15, 2026On June 15, 2026, NeoGenomics, Inc. (the “Company”) issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2032 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Convertible …Other event · Form 8-K
9. May 22, 2026On May 21, 2026, NeoGenomics, Inc. (the "Company") held an annual meeting (the "Annual Meeting") of its stockholders.Director or officer change · Form 8-K
10. Apr 28, 2026NeoGenomics Reports First Quarter 2026 Results.Earnings release · press release
11. Feb 17, 2026NeoGenomics Reports Fourth Quarter and.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.